On March 5, 2024 EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, reported the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, California between April 5-10, 2024 (Press release, EpimAb Biotherapeutics, MAR 5, 2024, View Source [SID1234640833]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This presentation will highlight the preclinical results for EMB-07, a novel ROR1 targeting TCE designed with an optimized efficacy, safety and pharmacokinetic profile. Furthermore, the presentation will discuss the TCE’s differentiated in vitro potency relative to benchmark molecules constructed using different modalities. The presentation details are as follows:
Title: Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
Session Date: April 8, 2024
Session Time: 9:00AM – 12:30PM local time
Presentation number: LB126 (poster section 52, number 14)
"With EMB-07 EpimAb is applying a unique and proprietary approach to target ROR1, a protein expressed on the surface of a multitude of solid and liquid tumor cells," Dr. Chengbin Wu, Founder and CEO of EpimAb commented. "We are very excited to share the preliminary preclinical findings for this bispecific at the AACR (Free AACR Whitepaper) Annual Meeting, and look forward to further unlocking the potential of our T-cell engager and bispecific antibody platforms to target diseases with unmet need and help patients around the world."
About EMB-07
EMB-07 is a novel ROR1×CD3 T-cell engaging bispecific antibody developed based on EpimAb’s proprietary bispecific antibody platforms. This molecule was carefully designed for an optimized efficacy and safety profile, as demonstrated by only modest levels of cytokine release in preclinical studies. EMB-07 is currently being evaluated in a Phase I trial in solid tumors and lymphomas (NCT05607498; CTR20230350).